MedWatch

Russian invasion of Ukraine could have multimillion-dollar impact on Novo Nordisk

1 percent of Novo Nordisk’s total sales could potentially be impacted by the war in Ukraine, said Novo exec Maziar Mike Doustdar at the company’s capital markets day.

Maziar Mike Doustdar, EVP of international operations at Novo Nordisk | Photo: Novo Nordisk / PR

It’s not yet fully known what Russia’s invasion of neighboring country Ukraine will mean for Denmark’s biggest pharmaceutical firm, Novo Nordisk.

Still, Maziar Mike Doustdar, EVP of international operations at Novo Nordisk, could partly unveil how much of the business could potentially be affected by the war in Ukraine in connection with the company’s capital markets day on Thursday, which transpired at Novo Nordisk headquarters in the Greater Copenhagen area.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs